One major advance in our understanding of prostate cancer pathogenesis is the recent seminal discovery that more than half of prostate cancers contain a fusion between TMPRSS2, a gene that is highly expressed in the prostate, and the ERG transcription factor. The role of TMPRSS2-ERG fusion in prostate cancer pathogenesis is poorly understood. A crucial limitation to our understanding is the lack of model systems. In this proposal, using three novel genetically-targeted mice, I will attempt to answer the following four questions: 1) where is TMPRSS2 expressed in the prostate and what is the fate of TMPRSS2-expressing cells? 2) what is the phenotype of mice expressing ERG under the TMPRSS2 promoter? 3) within the prostate, which cell types are sensitive to ERG-mediated transformation? and 4) what other genetic events cooperate with TMPRSS2-ERG fusion in carcinogenesis? First, I will generate a mouse expressing an inducible recombination enzyme (tamoxifen-inducible Cre) under the TMPRSS2 promoter, allowing detailed mapping of TMPRSS2 expression patterns and determination of the fate of TMPRSS2-expressing cells in the prostate. This mouse can also be used to activate oncogene/tumor suppressors in TMPRSS2-expressing cells when crossed with previously generated mice that have Cre inducible lesions. Second, I will target the ERG gene into the TMPRSS2 locus. This mouse will be assessed for tumor development, and the prostates will be studied in detail with histology and expression profiling. Third, I wilt target a Cre-inducible ERG into the ubiquitously expressed Rosa26 locus such that ERG will be specifically expressed when crossed with mice harboring tissue-specific Cre that is active in other prostate compartments. Fourth, to find genetic events that cooperate with TMPRSS2-ERG fusion, I will utilize both a candidate approach (crossing with previously generated mouse models harboring genetic lesions found in human prostate cancers) and an unbiased screen approach utilizing transposon mutagenesis that will specifically be activated in TMPRSS2 expressing cells. These studies will offer a comprehensive understanding of the role of TMPRSS2-ERG fusion in prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Ran, Leili; Chen, Yuedan; Sher, Jessica et al. (2018) FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discov 8:234-251
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Shukla, Shipra; Cyrta, Joanna; Murphy, Devan A et al. (2017) Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell 32:792-806.e7
Ran, Leili; Murphy, Devan; Sher, Jessica et al. (2017) ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors. Cancer Res 77:3758-3765
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Yang, Zhaohui; Peng, Yu-Ching; Gopalan, Anuradha et al. (2017) Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. Dis Model Mech 10:39-52
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Zhang, Pingzhao; Wang, Dejie; Zhao, Yu et al. (2017) Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med 23:1055-1062

Showing the most recent 10 out of 27 publications